Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And the market erupts as $3.83 floods in!! IMO unless and until JONATHAN LEINWAND and MARISSA WELNER, their MASTIFF GROUP LLC & Co are provably well and truly gone this ticker will likely remain a DUPE-and-DUMP scam.
They took over this ticker (fka TDEY) from Edward "Eddie" Vakser, got it uplisted to PINK CURRENT then destroyed existing shareholders with a 1-for-50,000 reverse split. $100 worth of stock pre R/S fell to $3-4 after.
Stella Diagnostics to Participate in BIO Investor Forum Digital
October 09, 2020 09:03 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Stella Diagnostics, Inc. (OTC Markets: JMDP – name change to STLA pending), a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease, today announced that Chief Executive Officer Dr. Joe Abdo will deliver a company presentation (Session ID 748685) and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13-15, 2020.
Stella Diagnostics was selected as the 2020 BIO Investor Forum Digital Buzz of BIO winner in the ‘Diagnostics and Beyond’ category. The Company’s presentation will be available on demand to registered participants through the conference website.
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s clinical assay will offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives.
Stella Diagnostics Selected as Buzz of BIO Winner for the 2020 BIO Investor Forum Digital
September 23, 2020 08:03 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Stella Diagnostics, Inc. (OTC Markets: JMDP), a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease, announced today that it was selected as the Buzz of BIO winner for the 2020 BIO Investor Forum Digital in the ‘Diagnostics and Beyond’ category. Stella Diagnostics also received an invitation to deliver a podium presentation about the company at the event to be held virtually on October 13-15, 2020.
The Buzz of BIO contest provides an excellent opportunity for companies to share their technology and commercial offerings. According to the BIO website, “…the BIO Investor Forum has become the premier event where biotech innovators can find strategic partners to advance their company to the next stage in their business life cycle.” The contest helps to identify U.S.-based companies with breakthrough, early stage technologies that have the potential to improve the lives of patients and yield an advantage in healthcare economics.
Joe Abdo, Co-founder and CEO of Stella Diagnostics said, “On behalf of the entire Stella team, we would like to thank BIO for nominating Stella as well as everyone who voted for Stella during the Buzz of BIO open voting competition. We are incredibly eager to demonstrate the paradigm shift that our diagnostic platform can bring to healthcare providers in the fields of gastroenterology, pathology and GI oncology.”
Scientific Advisor, Dr. Devendra Agrawal, noted that “Stella Diagnostics focuses on process innovation with the goal to deliver robust and actionable diagnostic data to providers treating millions of Americans living with severe esophageal disease. The technology was developed via rigorous research by domain experts and practicing physicians. We are looking forward to demonstrating to the BIO Investor Forum attendees how our discovery and algorithm can be incorporated into routine clinical sequences and concurrently yield critical diagnostic data in concert with standard of care screening protocols. This would allow the physicians and patients to make more informed decisions and achieve better outcomes.”
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s mass spec proteomic assay will offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit (www.stelladx.com).
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
JMD Properties, Inc. Acquires Diagnostic Oncology Company, Changes Focus to Biotech
September 02, 2020 09:26 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--JMD Properties, Inc. (OTC: JMDP) today announced it has acquired Stella Diagnostics, LLC, in a preferred stock acquisition and will be changing its name to Stella Diagnostics, Inc., to better express the new focus of the company.
Daniel Wainstein, the Chairman of the Board, noted, “the Company is confident that a move into the diagnostic sector of the biotech industry will be beneficial both to our investors and to all those suffering from serious esophageal disease which is an underserved and ever-growing patient population in the U.S. and abroad.”
Incoming CEO, Dr. Joe Abdo, said, “Six million Americans are living with Barrett’s esophagus which can be a precursor to the deadliest cancer relative to incidence in our country. Alarmingly, the rate of incidence of esophageal cancer is rising faster than any other cancer, with a 6-fold increase over two decades. Four out of five esophageal cancer patients present to their oncologist in the advanced stages of cancer progression, which is why survival durations are so short after diagnosis. Our mission at Stella Diagnostics is to stratify patients by disease severity with our multi-pronged diagnostic approach. In doing so, high risk patients will be identified when the disease is still in a treatable state. We are very excited about the transaction with JMDP which will provide Stella Diagnostics the resources to get our tests into the hands of patients and their providers quickly.”
In conjunction with the acquisition and name change, the Company will be filing for a symbol change. The Company will be filing this corporate action with FINRA.
About Stella Diagnostics, Inc.
Stella Diagnostics, Inc., is a molecular diagnostics-based organization focused on improving patient management strategies for the over 67 million people living with severe esophageal disease. The Company’s proprietary technology offers physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing, or turning cancerous. For more information, visit (www.stelladx.com).
Safe–Harbor
Forward Looking Statements: This press release may include forward-looking statements. These forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by use of the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project,” or similar expressions. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain and actual results may differ materially from those predicted in such forward looking statements. Factors that could have a material adverse effect on the operations and future prospects of the Company include, but are not limited to, changes in interest rates; the economic health of the local real estate markets in which we operate; general economic conditions; legislative/regulatory changes; monetary and fiscal policies of the U.S. government, including policies of the U.S. Treasury and the Federal Reserve Board; competition; and changes in accounting principles, policies, and guidelines. These risks and uncertainties should be considered in evaluating forward-looking statements, and undue reliance should not be placed on such statements.
BEWARE
JMD Properties, Inc. Acquires Diagnostic Oncology Company, Changes Focus to Biotech
https://www.businesswire.com/news/home/20200902005642/en/JMD-Properties-Acquires-Diagnostic-Oncology-Company-Focus
Jonathan Leinwand is a longtime penny-scam operator. Aside from being the attorney for Eddie Vakser's first ticker (ARTFEST INTERNATIONAL aka ARTS fka ARTI.OB).. Leinwand also represented it before the SEC which permanently revoked it for repeated lies.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142166169
Both are serial reverse splitters which destroy shareholders. Leinwand took over this ticker (fka TDEY) from Vakser via "reverse merger" then promptly pulled a 1-for-50,000 reverse split. If you held $100 worth of shares the day before your stake was soon carpet bombed down to around 5 cents.
Seems Leinwand and his "plus 1" Welner have found a sucker looking to go public "on the cheap" via a reverse merger. Yeah well, believe it when (if) it happens.
Stella's one page website was just registered at the end of may.
https://www.whois.com/whois/stelladx.com
It's address is the same one Leinwand & Weler operate from.
Did you open the link and scroll down just a bit?
What does it have to do with jmdp. And Edward vakster?
https://www.stelladx.com/investors/press-releases
new company direction looks interesting
0.151 equals 0.00000302 thanks to the 1-for-50,000 reverse split.
That's a fall of -97% from the .0001 per share this POS was priced at the day day before the R/S.
$100 invested before the R/S then is now worth THREE CENTS!!!!
Now these con artists claim they "acquired" an Oncology Company and will be doing yet ANOTHER name and ticker change.
Guess BURNING all their old shareholders to the ground with a MASSIVE 1 for 50,000 share REVERSE SPLIT a little over a year ago is wayyyyy in the past and their ready to fire it up again.
Strange as to why NONE of that fabulous news was posted by them on their Ihub page as PR.
0.55 STILL= loss of 90% after the 1-for-50,000 reverse split even on today's run.
The day before the R/S an investment of 1 million shares at .0001.= $100. The next day they found they held 20 shares priced at $5.00 which also= $100. How many would cheer a drop from $5.00 to .55?
"Up 2,000%"??? This doesn't even begin to qualify as a "dead cat bounce."
While management dropped the O/S massively with their devastating R/S their new lower appearing O/S was actually a giant increase in that they certainly didn't reduce it by the same 50,000.
Still a giant steaming POS
name change and 160k float, no brainer and news could run on volume imo even if its a shady one
New financials out on OTC Markets!! This FRAUD has grossed a total of $151.00 in the last FIVE YEARS. They grossed **GASP** $6.00 in 2019 after BURNING SHAREHOLDERS to the ground in March 2019 with that epic 1 for 50,000 REVERSE SPLIT and then pumping their real estate biz as if people were going to buy shares.
Bwhahahhahahhahaaaaaa!!!
Pfffttt....Of course it's all BS filings on OTC with no real details but what did em..."shareholders" expect?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147348480
Yup TDEY another Next month Edward failure. Add to the list
He pumped up tdey now after name change jmdp..... A Mj patented software that will produce a gazillion of revenues last year
Well it turned out all to be a big lie and on top. Of that he reverse split 1-50k and we losed it all
It’s the same message Next Month Edward post on all his FB accounts. All I can say, put up or shut up Edward. Maybe new name for Edward (Put Up or Shut Up Edward)
Link, I don't follow that 50K - 1 RS
Fast eddy Just posted on tdey
Scam run by slum landlords Leinwand and his "Plus One."
Hey Jonathan..what happened to that $5 million in financing you promised scam master Fast Eddie Vakser?
https://www.theinfostride.com/2014/03/protek-capital-luxuriant-holdings-inc-signs-funding-agreement/
https://backend.otcmarkets.com/otcapi/company/dns/news/document/8024/content
More--
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=99010725
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=100274932
New low on the board today .0003
Each million shares that BAGHOLDERS still have from the Eddie/LinDOOF days are now worth a six cents after they paid at least $100.00--$300.00+ per million for originally. Now there's a solid investment for you!!
You guys should find the "Gang of Four" who Eddie paid with FREE shares to PIMP this disaster when it was still TDEY. Oh the CASH that was going to flow in from software sales and bigggggg insurance contracts with AFLAC.
Hell...what could go wrong??
Typical slumlord scam behavior--Welner & Leinwand
https://www.wndu.com/content/news/Mastiff-Group-LLC-responsible-for-missing-payments-to-Mishawaka-Utilities-476617043.html
https://www.leagle.com/decision/innyco20191030838
Leinwand was the lawyer for Eddie Vakser's SEC revoked ARTFEST INTERNATIONAL. Here's their long, sorry, scammy history
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142166169
Why won’t it reflect on the ticker price?
Why does it not show on the new lows everyday on the ticker and stays at .10
If you divide the .0025 bid by 50,000
The 1-for-50,000 reverse split resulted in 50,000 shares priced at .0001 turning into one at $5.00. That $5.00 shares are now bid at .0025.
That's a drop of -99.95%.
Imagine how many zeroes you'd need if your .0001 shares fell another -99.95%. I don't even know how to calculate that!
.0050 is on the board why is it showing the wrong ticker price
Right at ONE YEAR ago these clowns and Eddie pulled a HUGE RS taking it to 5.00 per share--for about ONE SECOND after trading started.
Now a year later it's at 10 cents I'm thinking only because some DUMMY wanted shares at 5 cents and put in 50 cents. So a day or so later it's taken an 80% haircut down to 10 cents soon to be four cents that all the way to trips. Bawahahahhahaha!!
Peeps that had MILLIONS of shares of this FRAUD are 100% WIPED OUT.
Whose lawyer? What's the relevance to JMDP? TIA
the lawyer is Richard Garbarini
https://law.justia.com/cases/new-york/appellate-division-first-department/2010/2010-06151.html
From $5.00 per share the day this SHAM pulled their reverse split to 1.35 cents. LOL...now BAGHOLDERS shares are worth $2.70 per million owned. Boy,these new owners could teach Eddie and thing or two on how to DESTROY shareholders. But...those who bought were warned and warned and warned this would happen.
Every BAGHOLDER from the Eddie/LinDOOF days are WIPED OUT.
BTW,where is the "GANG OF FOUR" who helped Eddie PUMP this FRAUD--and no doubt got plenty of FREE shares to do so?? They've all been MIA since late 2015 when this POS PUMP and DUMP SHAM starring Kent LindOOF and Eddie collapsed.
Contracts with AFLAC???....Bawhahahahhahahaaaaaa!!!! SUCKERS!!!!
That hardly excuses Leinwand's years of pump-and-dump scamming.
Here's some binge reading
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142831370
Daniel Wainstein, Marissa Welner, and Jonathan Leinwand were sued by a Lawyer who had to withdraw the lawsuit and has been sanctioned by the bar several times.
Anyone look at who brought this lawsuit? The lawsuit was a total sham.
https://law.justia.com/cases/new-york/appellate-division-first-department/2010/2010-06151.html
Actually it would have to be over $10,000 per share for me to get even. The good news is I go through the reverse splits unscathed because they cant RS 1 share. I'm waiting to take the tax loss until the broker figures out my exact basis. I've been ignoring this for a decade and a half and it's time to take the loss. Got to get it off the books without paying a commission though.
Next thing you will say is PRPM will rs!
Wow !!! I’m impressed !
Edward Vakser--"presently..Chairman of JMD Properties, Inc."
Wall Street Journal
https://quotes.wsj.com/AURI/company-people/executive-profile/16448764
BIGGEST FRAUD ON THE OTC. Now....each million shares that BAGHOLDERS own (only 20 shares post RS) are worth a whopping $3.84.
Given that it would cost at LEAST $7 or 8.00 to sell a million of them Eddie and his cohorts have made all your millions of shares WORTHLESS. You'd need $5.00 just to break even. Think this FRAUD will ever see that pps again??
Oh well,they were WARNED for years this would happen BUT decided to listen to Eddie,LinDOOF and the "Gang of four" instead of FACTS.
When’s the next RS, sure EV waiting to push that RS button. I see Sister PRPM will be next and SUTI will follow after 3 Billion get diluted/added to O/S and AURI will get diluted to 3 Billion plus. Runs like Edward clock work. Prove me wrong Edward.
Followers
|
584
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
187251
|
Created
|
05/15/07
|
Type
|
Free
|
Moderators |
Stella Diagnostics, Inc. (OTC: SLDX) is a molecular diagnostics-based organization focused on improving patient management strategies for over 60 million people living with severe esophageal disease. Stella Diagnostics’ clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. |
|
| Stella Diagnostics (SLDX) Investor Deck |
Stella Diagnostics, Inc. | 50 West Broadway, Suite 300 | Salt Lake City, UT 84104 | info@stelladx.com | 1-201-381-1474 | www.stelladx.com |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |